Detail akcie Astra Zeneca online

Business Summary: AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, AstraZeneca plc revenues increased 3% to $45.81B. Net income increased 81% to $5.96B. Revenues reflect Farxiga segment increase of 36% to $5.96B, Imfinzi segment increase of 52% to $4.24B, Ultomiris segment increase of 51% to $2.97B, United States segment increase of 5% to $18.12B, Central America/Other South American Countries segment increase of 43% to $1.68B.